Jakob Dupont - Jan 3, 2022 Form 4 Insider Report for Atara Biotherapeutics, Inc. (ATRA)

Role
EVP, Head of R&D
Signature
/s/ David Tucker, Attorney-in-Fact for Jakob Dupont
Stock symbol
ATRA
Transactions as of
Jan 3, 2022
Transactions value $
-$32,150
Form type
4
Date filed
1/5/2022, 03:47 PM
Previous filing
Dec 3, 2021
Next filing
Feb 14, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ATRA Common Stock Options Exercise $47.9K +5K +5.52% $9.58 95.6K Jan 3, 2022 Direct F1
transaction ATRA Common Stock Sale -$80.1K -5K -5.23% $16.01* 90.6K Jan 3, 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATRA Employee Stock Option (Right to Buy) Options Exercise $0 -5K -1.87% $0.00 263K Jan 3, 2022 Common Stock 5K $9.58 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction pursuant to Rule 10b5-1 Plan adopted September 3, 2021.
F2 25% of the shares subject to the option vested on May 14, 2021 and the remaining shares vest in equal monthly installments over the following 36 months, subject to the reporting person's continuous service.